Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).
PROs Strengthen Case for Mirvetuximab Soravtansine as SOC in FRα+ Ovarian Cancer
March 16th 2024Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.
Read More